Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-160-4 | CAS number: 7789-38-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 007
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- Sodium bromate
- EC Number:
- 232-160-4
- EC Name:
- Sodium bromate
- Cas Number:
- 7789-38-0
- Molecular formula:
- BrHO3.Na
- IUPAC Name:
- sodium bromate
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: genitically modified: Tg.AC hemizygous, p53 haploinsufficient
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
Male and female FVB/N-TgN(v-Ha-ras) (Tg.AC) hemizygous (Tg.AC hemizygous) and B6.129-Trp53tmlBrd (N5) haploinsufficient (p53 haploinsufficient) mice were obtained from Taconic Laboratory Animals and Services (Germantown, NY) for use in the 26-, 27-, 39-, and 43-week studies. Tg.AC hemizygous mice were quarantined for 16 days before the beginning of the dermal studies and for 13 days before the beginning of the drinking water studies; p53 haploinsufficient mice were quarantined for 14 days before the beginning of the drinking water studies. Five male and five female mice per strain were randomly selected for parasite evaluation and gross observation of disease. Tg.AC hemizygous mice were 6 weeks old and p53 haploinsufficient mice were 6 to 8 weeks old at the beginning of the studies. Blood samples were collected from five male and five female sentinel mice per strain and study group at 4 and 26 weeks, from five male and five female mice from the highest surviving groups at 39 or 43 weeks, and from moribund mice in the 43-week drinking water studies.
ANIMAL MAINTENANCE:
Mice were housed individually and feed and water were available ad libitum. Water consumption was measured weekly by cage during the drinking water studies. Cages and racks were rotated every two weeks.
Administration / exposure
- Route of administration:
- other: dermal and oral via drinking water
- Vehicle:
- - Vehicle(s)/solvent(s) used:
Dermal application :40% USP-grade 95% ethanol/60% water
Drinking water: tap water - Duration of treatment / exposure:
- 26 weeks (dermal route); 27 weeks (drinking water)
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- dermal route
- Dose / conc.:
- 64 mg/kg bw/day
- Remarks:
- dermal route
- Dose / conc.:
- 128 mg/kg bw/day
- Remarks:
- dermal route
- Dose / conc.:
- 256 mg/kg bw/day
- Remarks:
- dermal route
- Dose / conc.:
- 0 mg/L drinking water
- Remarks:
- oral route
- Dose / conc.:
- 80 mg/L drinking water
- Remarks:
- oral route
- Dose / conc.:
- 400 mg/L drinking water
- Remarks:
- oral route
- Dose / conc.:
- 800 mg/L drinking water
- Remarks:
- oral route
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- 12-O-Tetradecanoylphorbol-13-acetate (TPA)
Examinations
- Tissues and cell types examined:
- Peripheral blood erythrocytes
- Details of tissue and slide preparation:
- At the end of the 26- and 27-week studies, peripheral blood samples were obtained from male and female mice. Smears were immediately prepared and fixed in absolute methanol. The methanol-fixed slides were stained with acridine orange and coded. Slides were scanned to determine the frequency of micronuclei in 2,000 normochromatic erythrocytes (NCEs) in each of up to 15 animals per group. In addition, the percentage of polychromatic erythrocytes (PCEs) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity.
- Statistics:
- The results were tabulated as the mean of the pooled results from all animals within a treatment group plus or minus the standard error of the mean. The frequency of micronucleated cells among NCEs was analyzed by a statistical software package that tested for increasing trend over dose or exposure groups with a one-tailed Cochran-Armitage trend test, followed by pairwise comparisons between each dosed or exposed group and the control group (ILS, 1990).
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- positive
- Remarks:
- Significant increases in micronucleated normochromatic erythrocytes (MN-NCE) were seen in Tg.AC hemizygous and p53 deficient mice.
- Toxicity:
- yes
- Remarks:
- Significant increases in the percentage of polychromatic erythrocytes among total erythrocytes were observed in Tg.AC hemizygous mice exposed via drinking water and dermally with NaBrO3.
- Vehicle controls validity:
- valid
- Remarks:
- only dermal route
- Negative controls validity:
- valid
- Remarks:
- only oral route
- Positive controls validity:
- valid
- Additional information on results:
- The genotoxic effects of sodium bromate was evaluated in a peripheral blood micronucleus assays on genetically modified (Tg.AC hemizygous and p53 haploinsufficient) mice (n= 10-15 per sex/dose).
Tg.AC hemizygous mice were treated dermally and orally (via drinking water); p53 haploinsufficient mice were exposed only through drinking water.
Sodium bromate exposure resulted in significantly increased frequencies of micronucleated erythrocytes in male and female Tg.AC hemizygous and p53 haploinsufficient mice administered the chemical in drinking water for 27 weeks or by dermal application for 26 weeks (Tg.AC hemizygous only). In all three micronucleus tests, a clear dose response was observed in male and female mice. Furthermore, significant increases in the percentage of polychromatic erythrocytes among total erythrocytes were observed in male and female Tg.AC hemizygous mice exposed via drinking water and in male Tg.AC hemizygous mice dosed dermally with sodium bromate. While, the percentage of polychromatic erythrocytes was not significantly altered in male or female p53 deficient mice.
Applicant's summary and conclusion
- Conclusions:
- Under the experimental conditions reported, sodium bromate induced a significant increase in the frequency of micronucleated erythrocytes in all Tg.AC hemizygotes and p53 haploinsufficient mice. Therefore, sodium bromate is considered to be mutagenic in the mammalian erythrocyte micronucleus test. However, in the carcinogenicity study reported in this publication, sodium bromate (> 99 % purity), did not show evidence of carcinogenic activity.
- Executive summary:
Three in vivo micronucleus tests in genetically modified mice were conducted by the National Toxicology Program (NTP) to assess the mutagenicity of sodium bromate (> 99 % purity) in peripheral blood cells derived from the bone marrow of the tested animals.
The genetically modified Tg.AC hemizygous mice (n= 15 per sex/dose) were treated by dermal application for 26 weeks or in drinking water for 27 weeks with sodium bromate at doses of 0, 64, 128 or 256 mg/kg bw (dermal route) or 0, 80, 400 or 800 mg/L (drinking water). p53 haploinsufficient mice (n= 15 per sex/dose) were were exposed to drinking water containing 0, 80, 400 or 800 mg/L sodium bromate for 27 weeks.
Sodium bromate exposure resulted in significantly increased frequencies of micronucleated erythrocytes in male and female Tg.AC hemizygous and p53 haploinsufficient mice. In all three in vivo micronucleus tests, a clear dose response was observed in male and female mice. Furthermore, significant increases in the percentage of polychromatic erythrocytes among total erythrocytes were observed in male and female Tg.AC hemizygous mice exposed via drinking water and in male Tg.AC hemizygous mice dosed dermally with sodium bromate. While, the percentage of polychromatic erythrocytes was not significantly altered in male or female p53 deficient mice.
Under the experimental conditions reported, sodium bromate induced a significant increase in the frequency of micronucleated erythrocytes in male and female mice Tg.AC hemizygotes and p53 haploinsufficient mice. Therefore, sodium bromate is considered to be mutagenic in the mammalian erythrocyte micronucleus test. However, in the carcinogenicity study reported in this publication, sodium bromate (> 99 % purity), did not show evidence of any carcinogenic activity. Thus, in an overall assessment of the entire data set, it is not possible to conclude on the classification for genotoxicity of sodium bromate (inconclusive).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.